SGPSpyGlass Pharma, Inc.同业对比
SpyGlass Pharma, Inc. 与SIC 3841 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGP本股 | $1.1B#5 | — | 4.6x#7 | — | — | -36.7%#10 | — | -17.2%#6 | — | — | — | — |
| KMTS | $1.8B#1 | — | 8.0x#9 | 18.6x#10 | 59.0%#1 | -15.6%#8 | -141.6%#10 | -59.2%#9 | -59.5%#5 | 4#4 | 8.1%#2 | — |
| NVCR | $1.5B#2 | — | 4.4x#6 | 2.4x#4 | 8.3%#8 | 19.4%#3 | -23.5%#6 | -38.9%#8 | -32.5%#4 | 3#6 | — | — |
| TNDM | $1.3B#3 | — | 10.0x#11 | 1.3x#2 | 7.9%#9 | -113.2%#11 | -18.5%#5 | -157.0%#11 | -26.3%#3 | 3#6 | — | — |
| PRCT | $1.1B#4 | — | 3.3x#5 | 3.6x#6 | 37.2%#3 | -4.5%#6 | -33.7%#7 | -0.0%#3 | -63.4%#6 | 2#8 | — | — |
| SIBN | $950M#6 | — | 5.2x#8 | 4.7x#7 | 20.2%#4 | 38.8%#1 | -11.1%#3 | -10.4%#4 | -12.0%#2 | 6#2 | — | — |
| BBNX | $875M#7 | — | 2.2x#1 | 8.7x#9 | 53.9%#2 | -33.7%#9 | -71.5%#9 | -18.2%#7 | — | — | — | — |
| KIDS | $810M#8 | — | 2.4x#3 | 3.4x#5 | 15.4%#6 | -4.8%#7 | -16.6%#4 | -11.7%#5 | -8.7%#1 | 4#4 | — | — |
| TCMD | $516M#10 | 22.4x#1 | 2.3x#2 | 1.6x#3 | 12.5%#7 | 12.5%#5 | 8.9%#2 | 8.4%#2 | — | — | 53.1%#1 | — |
| SGHT | $521M#9 | — | 9.9x#10 | 6.7x#8 | -3.1%#10 | 25.4%#2 | -48.0%#8 | -72.6%#10 | -266.6%#7 | 5#3 | — | — |
| MDXG | $506M#11 | — | 2.4x#4 | 1.2x#1 | 20.0%#5 | 14.5%#4 | 15.3%#1 | 23.0%#1 | — | 7#1 | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议